Skip to Content

Use of Corticosteroid Inhalers for the Treatment of Asthma and COPD to Increase

Upcoming Webinar from Decision Resources Will Explore Using Patient-Level Data to Quantify Lines of Therapy Within the Asthma and COPD Drug Markets

WALTHAM, Mass., January 10, 2007 -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the use of corticosteroid inhalers will increase for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

"Despite their criticisms of primary care physicians' use of inhaled corticosteroids, 39% of pulmonologists forecast that they will increase their use of these agents for treating COPD, presumably in large part because of the results of the TORCH study," said Decision Resources analyst Madhuri Borde, Ph.D. "For the treatment of asthma, physicians and experts concur that, over the next two years, they will likely increase their use of single-agent corticosteroid inhalers. Single-agent inhalers are becoming seen as the most appropriate first-line agent, though Advair use in this segment will continue to increase as well."

The findings come from two new reports from Decision Resources: Treatment Algorithms in Asthma and Treatment Algorithms in COPD. Information from the reports will be presented in a webinar on January 17th entitled "Using Patient-Level Data to Quantify Lines of Therapy within the Asthma and COPD Markets." For more information on how to attend the webinar, please contact Liz Marshall of Decision Resources at 781-296-2563.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithm Insight Series provide the following:

  • Summary of U.S. medical practice based on interviews with leading experts in the field
  • Qualitative diagnosis/referral/treatment algorithm for the United States
  • Drug usage by lines of therapy (1st, 2nd, 3rd line)
  • Discussion of key freeform combinations by lines of therapy
  • Product share (class and specific compound level) within each line of therapy (1st, 2nd, 3rd line)
  • Progression of therapy from key 1st line products
  • Pathway to key therapies from previous therapies
  • Qualitative analysis of two-year forecast incorporating upcoming launches, changes in reimbursement, etc.

Source: Decision Resources

Posted: January 2007